These stocks are moving in today's session
By Mill Chart
Last update: Mar 26, 2024
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Today's top gainers
| Ticker | Change | Comment |
|---|---|---|
| ETAO | 2.0K% | Investors witnessed a remarkable 2.0K% rise in ETAO INTERNATIONAL CO LTD's (NASDAQ:ETAO) shares, which climbed to $4.74 during Tuesday's session. In the last month the stock gained 37.59%. |
| MESO | 74.09% | MESOBLAST LTD- SPON ADR's (NASDAQ:MESO) stock price increased by 74.09% to $3.83. In the last year the stock lost 64.4%. |
| OPGN | 59.47% | With a 59.47% surge, OPGEN INC's (NASDAQ:OPGN) stock price reached $0.76 during Tuesday's session, signaling positive momentum. The company's earnings where released Yesterday. A press release (OpGen Announces Acquisition of Preferred Stock by David Lazar) was released yesterday. |
| CZOO | 58.52% | CAZOO GROUP LTD's (NYSE:CZOO) stock price displayed strong growth, advancing 58.52% and reaching $6.15 during Tuesday's session. In the last 3 months the share price dropped with 59.16%. |
| STOK | 57.0% | STOKE THERAPEUTICS INC (NASDAQ:STOK) experienced a significant 57.0% increase, reaching $10.21 during Tuesday's session. Yesterday the company had a press release: Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results. |
| DNUT | 39.52% | KRISPY KREME INC's (NASDAQ:DNUT) stock price increased by 39.52% to $17.37. A press release (McDonald’s® USA and Krispy Kreme® Announce Expanded National Partnership) was released yesterday. |
| CISS | 36.36% | C3IS INC's (NASDAQ:CISS) stock price displayed strong growth, advancing 36.36% and reaching $0.05 during Tuesday's session. Shareholders saw the stock price going 65.89% lower in the past month. |
| DERM | 30.7% | JOURNEY MEDICAL CORP (NASDAQ:DERM) rose 30.7% to $3.82 during Tuesday's after hours session. In the last month the stock lost 22.55%. |
| NUVB | 29.56% | Positive market sentiment drove NUVATION BIO INC's (NYSE:NUVB) stock price up by 29.56% to $2.92 during Tuesday's session. A press release (Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction) was released two days ago. |
| JEWL | 28.83% | Investors witnessed a remarkable 28.83% rise in ADAMAS ONE CORP's (NASDAQ:JEWL) shares, which climbed to $0.42 during Tuesday's session. Earlier today the company had a press release: Diamonds of Tomorrow: Adamas One Corp. (NASDAQ: JEWL) and the Lab-Grown Evolution. |
Our top gainers page will show you the full list.
Top losers
| Ticker | Change | Comment |
|---|---|---|
| NBSE | -51.21% | NEUBASE THERAPEUTICS INC's (NASDAQ:NBSE) shares fell 51.21% to $0.49. In the last 3 months the share price increased with 35.12%. |
| CDLX | -32.86% | CARDLYTICS INC's (NASDAQ:CDLX) stock price is declining with 32.86% to a price of $13.6. A press release (Cardlytics Announces Proposed Convertible Senior Notes Offering) was released yesterday. |
| EGOX | -26.33% | During Tuesday's session, NEXT.E.GO NV's (NASDAQ:EGOX) shares took a tumble, falling 26.33% to $0.04. The stock is trading 57.41% lower than a month ago. |
| GDS | -26.05% | There was a notable decline in GDS HOLDINGS LTD - ADR's (NASDAQ:GDS) shares, as they dropped 26.05% to $6.19 during Tuesday's session. The company's earnings where released Yesterday. A press release (GDS Appoints Jamie Khoo As CEO of GDS International) was released yesterday. |
| NCNC | -24.7% | NOCO-NOCO INC's (NASDAQ:NCNC) shares fell 24.7% to $0.25 during Tuesday's session. In the last month the share price increased with 75.95%. |
| GLUE | -22.1% | During Tuesday's session, MONTE ROSA THERAPEUTICS INC's (NASDAQ:GLUE) shares took a tumble, falling 22.1% to $6.59. Shareholders saw the stock price going 33.44% higher in the past month. |
| BLRX | -20.77% | BIOLINERX LTD-SPONS ADR's (NASDAQ:BLRX) stock price faced a 20.77% decline, reaching $1.03 during Tuesday's session. Shareholders saw the stock price going 28.57% lower is the past 6 months. |
| PNST | -20.29% | During Tuesday's session, PINSTRIPES HOLDINGS INC's (NYSE:PNST) shares took a tumble, falling 20.29% to $3.3. In the last month the stock gained 23.21%. |
| MVLA | -20.26% | MOVELLA HOLDINGS INC's (NASDAQ:MVLA) stock price is declining with 20.26% to a price of $0.09. In the last month the stock lost 55.0%. |
| WISA | -20.21% | WISA TECHNOLOGIES INC's (NASDAQ:WISA) stock price faced a 20.21% decline, reaching $0.02 during Tuesday's session. Earlier today the company had a press release: WiSA Technologies Announces Pricing of $2.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market. |
Our top losers page will show you the full list.
BIOLINERX LTD-SPONS ADR
NASDAQ:BLRX (5/14/2024, 9:20:10 AM)
0.63
+0.01 (+1.29%)
BLRX News
8 days ago - BioLineRxBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
a month ago - BioLineRx Ltd.BioLineRx Announces $6 Million Registered Direct Offering/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
2 months ago - InvestorPlaceBLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
2 months ago - BusinessInsiderBLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
2 months ago - BioLineRx Ltd.BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
2 months ago - BioLineRx LtdBioLineRx to Report 2023 Annual Financial Results on March 26, 2024/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
2 months ago - FinancialNewsMediaBiotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race WorthEQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
3 months ago - BioLineRx Ltd.BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
3 months ago - InvestorPlace3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondWhen you want to light your afterburners, these ideas will do the trick.
5 months ago - Seeking AlphaBioLineRx files for a $250M mixed securities shelf (NASDAQ:BLRX)BioLineRx (BLRX) has filed a prospectus for a mixed shelf offering to raise up to $250M, indicating potential growth in their financial capital.
5 months ago - BioLineRx Ltd.BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
6 months ago - Seeking Alphabiolinerx GAAP EPS of -$0.01 (NASDAQ:BLRX)BiolineRx, a biopharmaceutical company, reports Q3 2023 financial results, with a GAAP EPS of -$0.01.
